An official website of the United States government
Home
Name
Alectinib
Alternate Names
Alecensa
CH5424802
Abbreviations
None
Category
Chemotherapy
Subcategory
Tyrosine kinase inhibitor (TKI)
Targeted therapy (ALK, RET)
NSC Number
None
Primary Site
Lung
Histology
Non-small cell lung cancer (NSCLC)
Remarks
December 11, 2015 FDA granted accelerated approval to alectinib for the treatment of anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC) who have progressed or are intolerant to crizotinib (Xalkori).
November 6, 2017: FDA granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.
April 18, 2024 FDA approved alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer.
November 6, 2017: FDA granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.
April 18, 2024 FDA approved alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer.
Coding
This drug should be coded
